|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2600122001 |
|
最近更新日期: Date of Last Refreshed on: |
2026-04-08 09:19:57 |
|
注册时间: Date of Registration: |
2026-04-08 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
消化道内窥镜手术器械控制设备(FASTER系统) 辅助内镜下全层切除术治疗胃黏膜下肿瘤的有效性和安全性: 一项前瞻性、单盲、单中心、试点性随机对照试验 |
|
Public title: |
Efficacy and safety of gastrointestinal endoscopic surgical instrument control system (FASTER system)-assisted endoscopic full-thickness dissection for gastric submucosal tumors: a prospective, single-blind, single-center, pilot randomized controlled trial |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
消化道内窥镜手术器械控制设备(FASTER系统) 辅助内镜下全层切除术治疗胃黏膜下肿瘤的有效性和安全性: 一项前瞻性、单盲、单中心、试点性随机对照试验 |
|
Scientific title: |
Efficacy and safety of gastrointestinal endoscopic surgical instrument control system (FASTER system)-assisted endoscopic full-thickness dissection for gastric submucosal tumors: a prospective, single-blind, single-center, pilot randomized controlled trial |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
张天彧 |
研究负责人: |
钟芸诗 |
|
Applicant: |
Zhang Tianyu |
Study leader: |
Zhong Yunshi |
|
申请注册联系人电话: Applicant telephone: |
+86 153 9199 6658 |
研究负责人电话:
Study leader's |
+86 135 6462 3481 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
gladysiii705@163.com |
研究负责人电子邮件: Study leader's E-mail: |
zhong.yunshi@zs-hospital.sh.cn |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
上海市徐汇区枫林路180号 |
研究负责人通讯地址: |
上海市徐汇区枫林路180号 |
|
Applicant address: |
180 Fenglin Road, Xuhui District, Shanghai, China |
Study leader's address: |
180 Fenglin Road, Xuhui District, Shanghai, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
复旦大学附属中山医院 |
||
|
Applicant's institution: |
Zhongshan Hospital affiliated to Fudan University |
||
|
研究负责人所在单位: |
复旦大学附属中山医院;上海市徐汇区中心医院 |
||
|
Affiliation of the Leader: |
Zhongshan Hospital affiliated to Fudan University; Shanghai Xuhui Central Hospital |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
(2026)科审第(005)号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
上海市徐汇区中心医院伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of Shanghai Xuhui Central Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2026-04-01 00:00:00 | ||
|
伦理委员会联系人: |
欧美贤 |
||
|
Contact Name of the ethic committee: |
Ou Meixian |
||
|
伦理委员会联系地址: |
上海市龙川北路336号 |
||
|
Contact Address of the ethic committee: |
336 Longchuan North Road, Shanghai 200237, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 21 3668 2212 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
复旦大学附属中山医院;上海市徐汇区中心医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Zhongshan Hospital affiliated to Fudan University; Shanghai Xuhui Central Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
上海市徐汇区枫林路180号复旦大学附属中山医院 |
||||||||||||||||||||||
|
Primary sponsor's address: |
Zhongshan Hospital, Fudan University, 180 Fenglin Road, Xuhui District, Shanghai, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
复旦大学附属中山医院 |
||||||||||||||||||||||
|
Source(s) of funding: |
Zhongshan Hospital affiliated to Fudan University |
||||||||||||||||||||||
|
研究疾病: |
胃黏膜下肿瘤 |
||||||||||||||||||||||
|
Target disease: |
Gastric submucosal tumors |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
以标准的EFTR为对照,探究在胃黏膜下肿瘤的EFTR术中应用消化道内窥镜手术器械控制设备(FASTER系统)辅助以缩短手术时长的有效性及其安全性。 |
||||||||||||||||||||||
|
Objectives of Study: |
To evaluate the efficacy in reducing procedure time and the safety of gastrointestinal endoscopic surgical instrument control system (FASTER system)-assisted endoscopic full-thickness resection (EFTR), using standard EFTR as the control, in patients with gastric submucosal tumors. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
(1)年龄≥18岁且≤80岁; (2)术前体温正常; (3)术前胃镜、超声内镜、CT和MRI等评估为适合行EFTR的患者; (4)术前评估病灶为胃固有肌层来源的黏膜下肿瘤,且最大直径<5cm; (5)无合并其他胃和结直肠器质性疾病; (6)单次EFTR切除单个病灶; (7)患者和家属能够理解研究方案,愿意参与本研究并提供书面知情同意。 |
||||||||||||||||||||||
|
Inclusion criteria |
(1) Age >= 18 and <= 80 years; (2) Normal body temperature prior to surgery; (3) Preoperative assessments (including gastroscopy, endoscopic ultrasound, CT, and MRI) confirm suitability for EFTR; (4) Preoperative evaluation indicates a submucosal tumor originating from the gastric muscularis propria, with a maximum diameter <5 cm; (5) Absence of other organic diseases of the stomach and colorectum; (6) Single lesion to be resected in one EFTR procedure; (7) The patient and family members are capable of understanding the study protocol, willing to participate in the study, and able to provide written informed consent. |
||||||||||||||||||||||
|
排除标准: |
(1)年龄<18岁或>80岁; (2)免疫力低下者,或正在使用免疫抑制剂治疗者; (3)同时合并其他胃和结直肠器质性疾病患者; (4)既往胃手术史,可能影响本次术后结果的患者; (5)怀孕或哺乳期妇女; (6)严重肺气肿、间质性肺炎或缺血性心脏病等不能耐受麻醉及手术者; (7)患者具有EFTR手术禁忌; (8)患者或家属无法理解本研究的条件和目标。 |
||||||||||||||||||||||
|
Exclusion criteria: |
(1) Age <18 or >80 years; (2) Immunocompromised individuals, or those who undergoing treatment with immunosuppressive agents; (3) Patients with concurrent organic diseases of the stomach and colorectum; (4) Patients with a history of gastric surgery that may affect postoperative outcomes; (5) Pregnant or lactating women; (6) Patients with conditions such as severe emphysema, interstitial pneumonia, or ischemic heart disease who cannot tolerate anesthesia and surgery; (7) Patients with contraindications to EFTR; (8) Patients or family members are unable to understand the conditions and objectives of this study. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2026-04-10 00:00:00至 To 2026-08-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2026-04-10 00:00:00 至 To 2026-05-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
由独立分析师在https://edc.zs-hospital.sh.cn/auth/网站使用计算机中心生成随机序列 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Our independent analyst will generate a random sequence using the computer center on the website https://edc.zs-hospital.sh.cn/auth/. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
患者、病理学家和数据分析师在整个试验过程中对分组保持盲态。 |
|
Blinding: |
Patients, pathologists, and data analysts will remain blinded to the group allocation throughout the entire trial. |
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
None |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
CRF表和ResMan |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
CRF and ResMan |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |